| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - |
| 27 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
Pre-Funded Warrants to Purchase 6,500,000 Shares of Common Stock |
| 27 Oct 2026 | 424B5 |
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION October 27, 2026 ATI-052 Phase 1b Primary Analysis Results Atopic Dermatitis and Asthma |
| 21 Sep 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC and Cantor Fitzgerald & Co., as sales agents and/or principals (collectively the “Agents,” and each individually an “Agent”), are parties to tha... |
| 06 Aug 2026 | S-3ASR |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - |
| 04 Aug 2026 |
Form 4: Kolbeck Roland Wilhelm, Chief Scientific Officer
Received 36,375 shares by exercise or conversion · Gave up 12,385 shares to cover exercise price or tax ($64.4K) |
| 08 Jun 2026 |
Form 4: Mehra Anand, Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Schiff Andrew N, Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Humphries William D., Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Molineaux Christopher P., Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Milano Vincent, Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 08 Jun 2026 |
Form 4: Gowen Maxine, Director
Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2026, Aclaris Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s defi... |
Loading...